Bristol Myers Squibb Co (BMY)

Bristol-Myers Squibb Company (NYSE:BMY) is facing mixed analyst sentiment, with roughly 60% of covering analysts maintaining mixed ratings on the stock.

According to the report, geopolitical tensions, particularly the ongoing armed conflict in Iran, are weighing heavily on economists, who believe higher oil prices and broader uncertainty are intensifying...

In this article, we will look at Jim Cramer’s breakdown of 16 stocks, including pharma plays for rising oil.

On February 23, Piper Sandler boosted its price target for Bristol-Myers Squibb Company (NYSE:BMY) to $75 from $66 while keeping an Overweight rating on the company's shares.

On March 6, UBS raised its price recommendation on Bristol-Myers Squibb Company (NYSE:BMY) to $70 from $65 and maintained a Buy rating on the shares.

A February 26 report from CNBC said investors looking for stability have increasingly turned to companies with consistent dividend payments.

Global stock markets have continued to struggle as oil prices surged to their highest weekly spike in six years, with no signs of an imminent end to the Middle East conflict.

On February 25, RBC Capital initiated coverage of Bristol-Myers Squibb Company (NYSE:BMY) with a Sector Perform rating and a $60 price target.

According to a report from Franklin Templeton, dividends have played a much larger role in investor returns than many people realize.